Currently, Everon is optimizing several lead compounds: small molecules and
biologics that have already demonstrated a rejuvenation
effect in aging animals, as measured by a lowered mouse FI (similar FI has recently been accepted by FDA as a measure of aging
in the ongoing Metformin
human trial).